Phthalimide analogs as probable 15-lipoxygenase-1 inhibitors: synthesis, biological evaluation and docking studies
© Aliabadi et al. 2015
Received: 12 September 2014
Accepted: 6 July 2015
Published: 22 July 2015
Recent studies have been explained the role of lipoxygenases (LOX) in the origin of cancer. Among the lipoxygenases, the 5-LOX, 12-LOX and 15-LOX are more important in the cause of neoplastic disorders. In the present investigation, a new series of anticancer agents with 1,3,4-thiadiazole and phthalimide substructures were synthesized and their in vitro cytotoxicity was evaluated by MTT assay. Moreover, enzyme inhibitory potency was also assessed by enzymatic protocol towards 15-LOX-1. Molecular docking was performed to explore in silico binding mode of the target compounds.
Tested compounds showed a better cytotoxic activity against HT29 cell line (colorectal cancer) in comparison with other cell lines (PC3: prostate carcinoma; SKNMC: neuroblastoma). Unfortunately, all of the tested derivatives rendered lower inhibitory potency than quercetin towards 15-LOX-1. Four hydrogen bonds were detected in docking studies for compound 4d as the most potent derivative in enzymatic assay.
The biological results of reported compounds in this research were not so satisfactory. But, further structural modifications are necessary to improve the bioactivity of these derivatives.
KeywordsSynthesis Phthalimide 1,3,4-Thiadiazole Lipoxygenase Anticancer
Literature reviews declare that 1,3,4-thiadiazole ring as 5-membered heterocycle have diverse biological effects such as anti-inflammatory, anticonvulsant, antibacterial, antileshmanial, antioxidant and anticancer [9–20]. On the other hands, phthalimide moiety is another heterocyclic residue derived from the isoindole ring. This moiety has also exhibited several pharmacological activities like anticonvulsant, antitubercular, anti-inflammatory, anti-acetylcholinesterase as well as anticancer effects [21–31]. In the current investigation, we encouraged to synthesize a new series of chemical entities bearing 1,3,4-thiadiazole and phthalimide (isoindoline-1,3-dione) residues as potential anticancer agents.
The corresponding chemical reagents and starting materials were purchased from the commercial companies such as Merck and Sigma-Aldrich. The purification of the prepared compounds was carried out by column chromatography using ethyl acetate/petroleum ether. Spectroscopic methods were applied for characterization of the synthesized compounds. 1H NMR spectra were acquired by Bruker 250 MHz in deutrated chloroform (CDCl3) and the obtained data were expressed as δ (ppm) compared to tetramethylsilane (TMS) as internal standard. Infrared (IR) spectra of the prepared compounds were obtained by Shimadzu 470 with preparing potassium bromide (KBr) disk. The mass spectra were run on a Finigan TSQ-70 spectrometer (Finigan, USA) at 70 eV. Melting points were determined using electrothermal 9001 melting point analyzer apparatus and are uncorrected.
Synthesis of 2-(1,3-Dioxoisoindolin-2-yl)acetic acid (2)
5 g (33.8 mmol) of phthalic anhydride, 2.53 g (33.8 mmol) glycine and 4.67 ml (33.8 mmol) triethylamine (Et3N) were mixed in toluene (100 ml) and the reaction mixture was refluxed overnight (Scheme 1). The reaction was monitored by thin layer chromatography (TLC). Toluene was evaporated by rotary evaporator apparatus under reduced pressure. The obtained residue was washed by diethyl ether (Et2O) and n-hexane. The obtained white powder was used for the next step without any extra purification .
1HNMR (CDCl3, 250 MHz) δ (ppm): 4.3 (s, 2H, −CH2-), 7.70 (dd, 2H, J = 8.4 Hz, J = 2.4 Hz, H5,6-Phthalimide), 7.85 (dd, 2H, J = 8.4 Hz, J = 2.4 Hz, H4,7-Phthalimide), 11.97 (brs, −COOH). IR (KBr, cm−1) ῡ: 3468 (OH, acid), 3155, 2989, 2939, 1705 (C = O, acid). MS (m/z, %): 205 (M+, weak), 160 (100), 133 (20), 104 (40), 76 (35), 50 (20).
Synthesis of 2-(1,3-Dioxoisoindolin-2-yl)-N-(5-mercapto-1,3,4-thiadiazol-2-yl)acetamide (3)
3 g (14.63 mmol) of 2-(1,3-dioxoisoindolin-2-yl)acetic acid (compound 2), 2.80 g (14.63 mmol) N-ethyl-N-dimethylaminopropyl carbodiimide (EDC) and 1.98 g (14.63 mmol) hydroxybenzotriazole (HOBt) were mixed in 70 ml acetonitrile (CH3CN) and the obtained mixture was stirred for 30 min. Then, 1.95 g (14.63 mmol) of 5-amino-1,3,4-thiadiazole-2-thiol was added to the reaction mixture and the stirring was continued for 24 h. The reaction end was proved by thin layer chromatography (TLC). Then, acetonitrile was evaporated using rotary evaporator and the residue was washed by diethyl ether and n-hexane. More purification was done by column chromatogaraphy (petroleum ether/ethyl acetate 70/30) to afford a yellowish powder [33–35].
1HNMR (CDCl3, 250 MHz) δ (ppm): 4.81 (s, 2H, −CH2-CO-), 3.82 (s, 1H, SH), 7.89 (dd, 2H, J = 8.4 Hz, J = 2.4 Hz, H5,6-Phthalimide), 7.94 (dd, 2H, J = 8.4 Hz, J = 2.4 Hz, H5,6-Phthalimide), 13.81 (brs, NH). IR (KBr, cm−1) ῡ: 3201, 3070, 2924, 1739, 1608, 1554, 1465, 1377, 1307, 1053, 717. MS (m/z, %): 320 (10), 287 (80), 263 (60), 231 (100), 160 (80), 159 (60), 121 (40), 104 (40), 76 (45).
General procedure for synthesis of compounds 4a-4 l
In a flat bottom flask, 0.2 g (0.625 mmol) of 2-(1,3-dioxoisoindolin-2-yl)-N-(5-mercapto-1,3,4-thiadiazol-2-yl)acetamide (compound 3) was treated with 0.035 g (0.625 mmol) potassium hydroxide in absolute ethanol and heated for 5 min, then equimolar (0.625 mmol) quantity of appropriate benzyl chloride derivative was added to the reaction medium and reflux condition was performed for 24 h. Thin layer chromatography (TLC) was carried out to determine the reaction end. Then, crushed ice was added to the reaction flask and the formed precipitate was filtered and collected. Crystallization was performed using ethanol .
1HNMR (CDCl3, 250 MHz) δ (ppm): 4.79 (s, 2H, −S-CH2-), 4.89 (s, 2H, −CH2-CO-), 7.45 (t, 1H, H4-2-Nitrophenyl), 7.57 (m, 2H, H5,6-2-Nitrophenyl), 7.81 (dd, 2H, J = 8.4 Hz, J = 2.4 Hz, H5,6-Phthalimide), 7.95 (dd, 2H, J = 8.4 Hz, J = 2.4 Hz, H5,6-Phthalimide), 8.06 (d, 1H, J = 10 Hz, H3-2-Nitrophenyl). IR (KBr, cm−1) ῡ: 3414, 3325, 3170, 3035, 2927, 2854, 2742, 1774, 1720, 1573, 1523, 1415, 1346, 1303, 1195, 952, 713.
1HNMR (CDCl3, 250 MHz) δ (ppm): 4.45 (s, 2H, −S-CH2-), 4.77 (s, 2H, −CH2-CO-), 7.48-7.59 (m, 2H, 3-Nitrophenyl), 7.73 (dd, 2H, J = 8.4 Hz, J = 2.4 Hz, H5,6-Phthalimide), 7.92 (d, 1H, J = 7.5 Hz, H4-3-Nitrophenyl), 8.24 (dd, 2H, J = 8.4 Hz, J = 2.4 Hz, H4,7-Phthalimide), 8.36 (s, 1H, H2-3-Nitrophenyl). IR (KBr, cm−1) ῡ: 3429, 3209, 3066, 2924, 2854, 1774, 1708, 1527, 1411, 1350, 1296, 1195, 1053, 952, 717. MS (m/z, %): 455 (M+, Weak), 398 (15), 268 (100), 235 (35), 193 (45), 136 (55), 109 (15), 89 (30), 60 (35).
1HNMR (CDCl3, 250 MHz) δ (ppm): 4.42 (s, 2H, −S-CH2-), 4.79 (s, 2H, −CH2-CO-), 7.52 (d, 2H, J = 10 Hz, H2,6-4-Nitrophenyl), 7.79 (dd, 2H, J = 8.4 Hz, J = 2.4 Hz, H5,6-Phthalimide), 7.91 (dd, 2H, J = 8.4 Hz, J = 2.4 Hz, H4,7-Phthalimide), 8.2 (d, 2H, J = 10 Hz, H2,6-4-Nitrophenyl). IR (KBr, cm−1) ῡ: 3421, 3352, 3113, 2927, 2850, 1774, 1720, 1519, 1415, 1346, 1303, 1107, 952, 713. MS (m/z, %): 455 (M+, Weak), 398 (12), 268 (100), 235 (20), 193 (90), 136 (30), 109 (25), 89 (60), 60 (40).
1HNMR (CDCl3, 250 MHz) δ (ppm): 3.74 (s, 3H, −OCH3), 4.38 (s, 2H, −S-CH2-), 4.86 (s, 2H, −CH2-CO-), 6.77 (d, 1H, J = 10 Hz, H4-3-Methoxyphenyl), 6.92 (m, 2H, H2, H6 -3-Methoxyphenyl), 7.20 (t, 1H, J = 7.5 Hz, H5-3-Methoxyphenyl), 7.77 (dd, 2H, J = 8.4 Hz, J = 2.4 Hz, H5,6-Phthalimide), 7.92 (dd, 2H, J = 8.4 Hz, J = 2.4 Hz, H4,7-Phthalimide). IR (KBr, cm−1) ῡ: 3425, 3329, 3170, 3035, 2927, 2850, 1720, 1624, 1577, 1415, 1303, 1269, 1159, 1049, 952, 713. MS (m/z, %): 440 (M+, 10), 160 (40), 121 (100), 104 (45), 92 (20), 76 (35), 65 (60), 52 (55).
1HNMR (CDCl3, 250 MHz) δ (ppm): 3.76 (s, 3H, −OCH3), 4.35 (s, 2H, −S-CH2-), 4.85 (s, 2H, −CH2-CO-), 6.82 (d, 2H, J = 7.5 Hz, H3,5-4-Mehoxyphenyl), 7.28 (d, 2H, J = 7.5 Hz, H2,6-4-Mehoxyphenyl), 7.77 (dd, J = 8.4 Hz, J = 2.4 Hz, 2H, H5,6-Phthalimide), 7.92 (dd, 2H, J = 8.4 Hz, J = 2.4 Hz, H5,6-Phthalimide). IR (KBr, cm−1) ῡ: 3325, 3248, 3132, 3035, 2927, 2850, 1774, 1705, 1627, 1577, 1419, 1307, 1246, 1195, 1180, 1064, 952. MS (m/z, %): 440 (M+, Weak), 249 (10), 193 (10), 160 (60), 121 (100), 104 (30), 92 (40), 76 (75), 65 (70), 52 (45).
1HNMR (CDCl3, 250 MHz) δ (ppm): 4.47 (s, 2H, S-CH2-), 4.83 (s, −CH2-CO-), 7.04-7.09 (m, 4H, 2-Fluorophenyl), 7.79 (dd, 2H, J = 8.4 Hz, J = 2.4 Hz, H5,6-Phthalimide), 7.91 (dd, 2H, J = 8.4 Hz, J = 2.4 Hz, H4,7-Phthalimide). IR (KBr, cm−1) ῡ: 3429, 3329, 3170, 2924, 2854, 2738, 1774, 1720, 1624, 1573, 1492, 1415, 1303, 1195, 952, 759. MS (m/z, %): 428 (M+, 12), 371 (25), 241 (20), 166 (30), 109 (100), 83 (10).
2-(1,3-Dioxoisoindolin-2-yl)-N-(5-(3-fluorobenzylthio)-1,3,4-thiadiazol-2-yl)acetamide (4 g)
1HNMR (CDCl3, 250 MHz) δ (ppm): 4.39 (s, 2H, −S-CH2-), 4.85 (s, 2H, −CH2-CO-), 6.92 (t, 1H, J = 7.5 Hz, H5-3-Fluorophenyl), 7.11 (m, 2H, H4, H6 -3-Fluorophenyl), 7.24 (m, 1H, H2-3-Fluorophenyl), 7.77 (dd, 2H, J = 8.4 Hz, J = 2.4 Hz, H5,6-Phthalimide), 7.92 (dd, 2H, J = 8.4 Hz, J = 2.4 Hz, H5,6-Phthalimide), 13.70 (brs, NH). IR (KBr, cm−1) ῡ: 3444, 3170, 3035, 2924, 2854, 1774, 1720, 1566, 1415, 1300, 952, 713. MS (m/z, %): 428 (M+, 15), 371 (30), 241 (40), 166 (25), 109 (100), 83 (10).
2-(1,3-Dioxoisoindolin-2-yl)-N-(5-(4-fluorobenzylthio)-1,3,4-thiadiazol-2-yl)acetamide (4 h)
1HNMR (CDCl3, 250 MHz) δ (ppm): 4.36 (s, 2H, −S-CH2-), 4.86 (s, 2H, −CH2-CO-), 6.99 (t, 2H, H2,6-4-Fluorophenyl), 7.32 (t, 2H, H3,5-4-Fluorophenyl), 7.77 (dd, 2H, J = 8.4 Hz, J = 2.4 Hz, H5,6-Phthalimide), 7.92 (dd, 2H, J = 8.4 Hz, J = 2.4 Hz, H4,7-Phthalimide). IR (KBr, cm−1) ῡ: 3433, 3329, 3159, 3039, 2927, 2850, 1774, 1720, 1624, 1573, 1508, 1415, 1303, 1226, 1087, 952, 831, 713. MS (m/z, %): 428 (10), 371 (20), 241 (10), 166 (40), 109 (100), 83 (12).
1HNMR (CDCl3, 250 MHz) δ (ppm): 4.54 (s, 2H, −S-CH2-), 4.87 (s, 2H, −CH2-CO-), 7.20 (m, 2H, H3,6-2-Chlorophenyl), 7.35 (t, 1H, H4-2-Chlorophenyl), 7.43 (t, 1H, H5-2-Chlorophenyl), 7.77 (dd, 2H, J = 8.4 Hz, J = 2.4 Hz, H5,6-Phthalimide), 7.92 (dd, 2H, J = 8.4 Hz, J = 2.4 Hz, H4,7-Phthalimide). IR (KBr, cm−1) ῡ: 3475, 3429, 3170, 3051, 2927, 2858, 2738, 1774, 1720, 1566, 1469, 1415, 1300, 1195, 952, 713. MS (m/z, %): 446 (M++2, 4), 444 (M+, 10), 284 (12), 162 (10), 160 (85), 125 (100), 104 (10), 76 (15).
1HNMR (CDCl3, 250 MHz) δ (ppm): 4.37 (s, 2H, −S-CH2-), 4.85 (s, 2H, −CH2-CO-), 7.24 (m, 3H, 3-Chlorophenyl), 7.41 (s, 1H, H2-3-Chlorophenyl), 7.77 (dd, 2H, J = 8.4 Hz, J = 2.4 Hz, H5,6-Phthalimide), 7.92 (dd, 2H, J = 8.4 Hz, J = 2.4 Hz, H4,7-Phthalimide). IR (KBr, cm−1) ῡ: 3325, 3170, 3055, 2927, 2850, 1720, 1627, 1573, 1400, 1300, 1203, 1111, 1083, 1049, 956, 713, 648. MS (m/z, %): 446 (M++2, 5), 444 (M+, 15), 162 (25), 160 (50), 125 (100), 104 (30), 76 (35).
N-(5-(4-Chlorobenzylthio)-1,3,4-thiadiazol-2-yl)-2-(1,3-dioxoisoindolin-2-yl)acetamide (4 k)
1HNMR (CDCl3, 250 MHz) δ (ppm): 4.35 (s, 2H, −S-CH2-), 4.85 (s, 2H, −CH2-CO-), 7.28 (dd, 4H, 4-Chlorophenyl), 7.77 (dd, 2H, J = 8.4 Hz, J = 2.4 Hz, H5,6-Phthalimide), 7.91 (dd, 2H, J = 8.4 Hz, J = 2.4 Hz, H5,6-Phthalimide). IR (KBr, cm−1) ῡ: 3325, 3155, 3059, 3035, 2927, 2850, 1774, 1720, 1627, 1573, 1492, 1303, 1091. MS (m/z, %): 446 (M++2, 5), 444 (M+, 12), 284 (5), 162 (15), 160 (90), 125 (100), 104 (20), 76 (25).
N-(5-(Benzylthio)-1,3,4-thiadiazol-2-yl)-2-(1,3-dioxoisoindolin-2-yl)acetamide (4 l)
1HNMR (CDCl3, 250 MHz) δ (ppm): 4.39 (s, 2H, −S-CH2-), 4.86 (s, 2H, −CH2-CO-), 7.23-7.37 (m, 5H, Phenyl), 7.77 (dd, 2H, J = 8.4 Hz, J = 2.4 Hz, H5,6-Phthalimide), 7.92 (dd, 2H, J = 8.4 Hz, J = 2.4 Hz, H4,7-Phthalimde). IR (KBr, cm−1) ῡ: 3425, 3329, 3170, 3032, 2927, 2850, 1720, 1627, 1573, 1546, 1415, 1396, 1303, 1195, 1111, 952, 709. MS (410, M+), 160 (75), 91 (100), 77 (10).
Synthesized derivatives (compounds 4a-4 l) were tested for cytotoxic activity at 0.1-100 μM concentration in three human cancer cell lines of PC3 (Prostate carcinoma), HT29 (Colorectal cancer) and SKNMC (Neuroblastoma). Cells were purchased from the Pasteur Institute of Iran. Cells from different cell lines were seeded in 96-well plates at the density of 8000–10,000 viable cells per well and incubated for 24 h to allow cell attachment. The cells were then incubated for another 24 h with various concentrations of compounds 4a-4 l. Cells were then washed in PBS, and 20 μL of MTT (3–(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide solution (5 mg/mL) were added to each well. An additional 4 h of incubation at 37 °C were done, and then the medium was discarded. Dimethyl sulfoxide (60 μL) was added to each well, and the solution was vigorously mixed to dissolve the purple tetrazolium crystals. The absorbance of each well was measured by plate reader (Anthous 2020; Austria) at a test wavelength of 550 nm against a standard reference solution at 690 nm. The amount of produced purple formazan is proportional to the percentage of cell viability [33–35].
The basis of this method is oxidative coupling of 3-methyl-2-benzothiazolinone hydrazone (MBTH) with 3 (dimethylamino) benzoic acid (DMAB) in a hemoglobin catalyzed reaction. This reaction is initiated in the presence of lipoxygenase reaction product, linoleic acid hydroperoxide and results in a blue color formation which has a peak absorbtion at 590 nm . Quercetin was used as the reference compound. Linoleic acid and two stock solutions (A and B) were prepared first. Solution A contained 50 mM DMAB and l00 mM phosphate buffer (pH = 7.0). Solution B was prepared by mixing 10 mM MBTH (3 mL) and hemoglobin (5 mg/mL, 3 mL) in 50 mM phosphate buffer at pH 5.0 (25 mL). A linoleic acid solution (1 mg/ml) was prepared by diluting 5 mg linoleic acid (solubilised in 0.5 ml ethanol) with KOH 100 mM.
For each compound the samples were solved in ethanol (25 μl) and mixed in a test tube with SLO (4000 units/mL, prepared in 50 mM phosphate buffer pH = 7.0, 25 μL) and phosphate buffer (50 mM, pH = 7, 900 μL). After a 5 min delay at room temperature, 50 μL linoleic acid was added to the mixture to start the hydroperoxidation reaction. After 8 min, solution A (270 μL) and solution B (130 μL) were added to the above mixture. 5 min later, 200 μL of SDS solution (2 %) was added to stop the reaction. The absorbance at 590 nm was compared with control (ethanol without sample).
The related protein structure was downloaded from brookhaven protein data bank (http://RCSB.org). Namely, 15-Lipoxygenase-1 in complex with dihydroxybenzoic acid (pdb code: 1N8Q) was utilized. ArgusLab software 4.0 was used for drawing the chemical structures and then energy minimization was carried out using AM1 as semiemperical method . The related ligand groups as well as binding site groups were defined. The binding location of dihydroxybenzoic aicd was defined as binding site for searching the best pose and conformation for all ligands. The geometry optimization of the protein structure was done by universal force field (UFF) as molecular mechanic method. Binding mode and related interactions of ligands with lipoxygense enzyme were explored in ArgusLab software.
Results and discussion
Properties of synthesized compounds
Synthesized compounds were characterized by spectroscopic methods such as 1H NMR, IR and MS and corresponding melting points were also measured. Compound 4a with ortho nitro moiety rendered the lowest melting point (179 °C) among the final products and compounds 4e with para methoxy group demonstrated the highest melting point (259 °C) in these series. 1H NMR spectra were acquired in deutrated chloroform (CDCl3). In the most cases the acidic property of the proton of the amidic bond (NH group) was caused to not be appeared in the NMR spectra. Phthalimide group as well as 1,3,4-thiadiazole ring function as electron withdrawing groups and these have an important role in enhancing the acidic property of the hydrogen of NH group.
Three cancerous cell lines were used to test the anticancer activity of the final compounds 4a-4 l. PC3 (Prostate carcinoma), HT29 (colorectal cancer) and SKNMC (neuroblastoma) was cultured and intended derivatives were assessed at concentration 0.1-100 μM and the obtained results were compared to doxorubicin as reference drug. None of the tested compounds showed superior cytotoxic effect than doxorubicin at tested concentrations towards the utilized cell lines. Generally tested derivatives exerted a better cytotoxic activity against HT29 cell line compared to other cell lines. PC3 and SKNMC cell lines were the most resistant cell lines to the tested compounds. None of the introduced moieties containing electron withdrawing groups and electron donating groups on the phenyl residue were efficacious to produce a remarkable anticancer activity.
Biological data of synthesized compounds. Results of the cytotoxicity assay were reported as IC50 ± SD (μM)
15-Lipoxygenase-1 (% of inhibition)a
10.91 ± 4.1
50.2 ± 5.4
88.83 ± 4.3
81.92 ± 4.7
89.21 ± 5.7
24.06 ± 3.1
69.7 ± 3.6
3.8 ± 0.75
2.1 ± 0.26
1.3 ± 0.4
Structure activity relationship
Enzyme inhibitory effect of the final prepared compounds was investigated towards 15-lipoxygense-1 and obtained results were listed in Table 2. None of the tested derivatives exerted favorable inhibitory potency towards 15-LOX-1 at 200 μM concentration compared to quercetin as reference compound. Quercetin as naturally occurring compound showed 100 % inhibition at 200 μM concentration. Among the tested derivatives, compound 4d with meta positioning of the methoxy group afforded the highest inhibitory effect (38 %). Movement of the methoxy to the para position caused a detrimental effect and decreased the inhibitory activity. Nitro containing compounds (4a, 4b, 4c) as well as para chlorine containing compound (4 k) did not demonstrated any inhibitory activity at tested concentration. Fluorine containing derivatives also exhibited a high inhibitory activity compared to others. This inhibitory activity was more observable while the fluorine substituted at position ortho and para. It is probable that electron withdrawing effect of this moiety is a critical factor to increase the enzyme inhibitory effect. Replacement of the fluorine substituent with chlorine caused a decrease in activity. Chlorine atom has a greater size and lipophilicity than fluorine and it is likely that these parameters induce a negative effect on interaction of the ligands to the corresponding receptor.
Three cancerous cell lines were used to evaluate the in vitro cytotoxicity potency of synthesized derivatives. Unfortunately, tested compounds did not display a remarkable activity against utilized cell lines (Table 2). Only compounds 4f (ortho fluorine) and 4 k (para chlorine) rendered an acceptable cytotoxic potency against HT29 cell line. None of the nitro and methoxy substituted derivatives exerted an inhibitory potency (IC50) up to 100 μM concentration. Substitution of the fluorine at meta position of the phenyl residue caused an enhancement in cytotoxic activity towards SKNMC cell line. Para positioning of the fluorine was also caused a brief increase in anticancer activity in PC3 cell line. A descending trend in IC50 was seen from compound 4i (o-Cl) to 4 k (p-Cl) against PC3 cell line. But, a reverse trend was demonstrated for chlorinated derivatives against HT29 and SKNMC cell lines. Steric factor and lipophilicity effects produced by chlorine atom maybe a probable reason for this observation.
Based on the above mentioned information, there is not any direct correlation between the cytotoxic activity and inhibition of lipoxygenase. According to the previously reported literature [34, 35], it could be hypothesized that inhibition of tyrosine kinases is the probable of cytotoxicity of these compounds.
A new series of compounds with combination of 1,3,4-thiadiazole and phthalimide substructures were synthesized and their cytotoxicity was evaluated in vitro using MTT protocol. Furthermore, synthesized derivatives were tested in an enzymatic assay for exploration of the inhibitory activity towards 15-lipoxygenase-1. According to the obtained results in MTT assay as well as enzymatic experiment, the investigated compounds did not show a favorable anticancer activity. Amongst them, only compounds 4f (ortho fluorine) and 4 k (para chlorine) exhibited an acceptable cytotoxic potency towards HT29 cell line. Hence, further structural modifications are needed to achieve derivatives with superior activity.
The authors are acknowledged from the research council of Kermanshah University of Medical Sciences due to financial support of the current research. This work was performed in partial fulfillment of the requirement for PharmD of Mrs Zeinab Hossseinzadeh.
- Rioux N, Castonguay A. Inhibitors of lipoxygenase: a new class of cancer chemopreventive agents. Carcinogenesis. 1998;8:1393–400.View ArticleGoogle Scholar
- Tong WG, Ding XZ, Adrian TE. The mechanisms of lipoxygenase inhibitor-induced apoptosis in human breast cancer cells. Biochem Biophys Res Commun. 2002;296:942–8.PubMedView ArticleGoogle Scholar
- Steele VE, Holmes CV, Hawk ET, Kopelovich L, Lubet RA, Crowell JA. Lipoxygenase inhibitors as potential cancer chemopreventives. Cancer Epidemiol Biomarkers Prev. 1999;8:467–83.PubMedGoogle Scholar
- Shureiqi I, Chen D, Jack Lee J, Yang P, Newman RA, Brenner DE, et al. 15-LOX-1: a novel molecular target of nonsteroidal anti-inflammatory drug-Induced apoptosis in colorectal cancer cells. J Natl Cancer Inst. 2000;14:1136–42.View ArticleGoogle Scholar
- Shureiqi I, Lippman SM. Lipoxygenase modulation to reverse carcinogenesis. Cancer Res. 2001;61:6307–12.PubMedGoogle Scholar
- Kelavkar UP, Nixon JB, Cohen C, Dillehay D, Eling TE, Badr KF. Overexpression of 15-lipoxygenase-1 in PC-3 human prostate cancer cells increases tumorigenesis. Carcinogenesis. 2001;11:1765–73.View ArticleGoogle Scholar
- Shureiqi I, Xu X, Chen D, Lotan R, Morris JS, Fischer SM. Nonsteroidal anti-Inflammatory drugs induce apoptosis in esophageal cancer cells by restoring 15-Lipoxygenase-1 expression. Cancer Res. 2001;61:4879–84.PubMedGoogle Scholar
- Mahdavi M, Shirazi MS, Taherkhani R, Saeedi M, Alipour E, Moghadam FH, et al. Synthesis, biological evaluation and docking study of 3-aroyl-1-(4-sulfamoylphenyl)thiourea derivatives as 15-lipoxygenase inhibitors. Eur J Med Chem. 2014;82:308–13.PubMedView ArticleGoogle Scholar
- Asadipour A, Edraki N, Nakhjiri M, Yahya-Meymandi A, Alipour E, Saniee P, et al. Anti-Helicobacter pylori activity and structure-activity relationship study of 2-Alkylthio-5-(nitroaryl)-1,3,4-thiadiazole derivatives. Iran J Pharm Res. 2013;3:281–7.Google Scholar
- Mohammadhosseini N, Saniee P, Ghamaripour A, Aryapour H, Afshar F, Edraki N, et al. Synthesis and biological evaluation of novel benzyl piperazine derivatives of 5-(5-nitroaryl)-1,3,4-thiadiazoles as Anti-Helicobacter pylori agents. Daru: J Pharm Sci. 2013;1:66.View ArticleGoogle Scholar
- Moshafi MH, Sorkhi M, Emami S, Nakhjiri M, Yahya-Meymandi A, Negahbani AS, et al. 5-Nitroimidazole-based 1,3,4-thiadiazoles: heterocyclic analogs of metronidazole as anti-Helicobacter pylori agents. Arch Pharm Chem Life Sci. 2011;344(3):178–83.View ArticleGoogle Scholar
- Rajak H, Deshmukh R, Aggarwal N, Kashaw S, Kharya MD, Mishra P. Synthesis of novel 2,5-disubstituted 1,3,4-thiadiazoles for their potential anticonvulsant activity: pharmacophoric model studies. Arch Pharm Chem Life Sci. 2009;342:453–61.View ArticleGoogle Scholar
- Abdel-Aziz M, Aly OM, Khan SS, Mukherjee K, Bane S. Synthesis, Cytotoxic properties and tubulin polymerization inhibitory activity of novel 2-pyrazoline derivatives. Arch Pharm Chem Life Sci. 2012;345:535–48.View ArticleGoogle Scholar
- Mishra G, Singh AK, Jyoti K. Review article on 1,3,4-Thiadiazole derivatives and its pharmacological activities. Int J Chem Tech Res. 2011;3:1380–93.Google Scholar
- Singh AK, Mishra G, Jyoti K. Review on Biological Activities of 1,3,4-Thiadiazole derivatives. J App Pharm Sci. 2011;5:44–9.Google Scholar
- Kalidhar U, Kaur A. 1,3,4-Thiadiazole derivatives and their biological activities: A Review. Res J Pharm Biol Chem. 2011;4:1091–106.Google Scholar
- Siddiqui N, Ahuja P, Ahsan W, Pandeya SN, Alam MS. Thiadiazoles: progress report on biological activities. J Chem Pharm Res. 2009;1:19–30.Google Scholar
- Behrouzi-Fardmoghadam M, Poorrajab F, Kaboudanian Ardestani S, Emami S, Shafiee A, Foroumadi A. Synthesis and in vitro anti-leishmanial activity of 1-[5-(5-nitrofuran-2-yl)-1,3,4-thiadiazol-2-yl]- and 1-[5-(5-nitrothiophen-2-yl)-1,3,4-thiadiazol-2-yl]-4-aroylpiperazines. Bioorg Med Chem. 2008;16:4509–15.PubMedView ArticleGoogle Scholar
- Poorrajab F, Kaboudanian Ardestani S, Emami S, Behrouzi-Fardmoghadam M, Shafiee A, Foroumadi A. Nitroimidazolyl-1,3,4-thiadiazole-based anti-leishmanial agents: Synthesis and in vitro biological evaluation. Eur J Med Chem. 2009;4:1758–62.View ArticleGoogle Scholar
- Mirzaei J, Siavoshi F, Emami S, Safari F, Khoshayand MR, Shafiee A, et al. Synthesis and in vitro anti-Helicobacter pylori activity of N-[5-(5-nitro-2-heteroaryl)-1,3,4-thiadiazol-2-yl]thiomorpholines and related compounds. Eur J Med Chem. 2008;8:1575–80.View ArticleGoogle Scholar
- Kok SHL, Gambari R, Chui CH, Yuen MCW, Lin E, Wong RSM, et al. Synthesis and anti-cancer activity of benzothiazole containing phthalimide on human carcinoma cell lines. Bioorg Med Chem. 2008;16:3626–31.PubMedView ArticleGoogle Scholar
- Yang YJ, Yang YN, Jiang JS, Feng ZM, Liu HY, Pan XD, et al. Synthesis and cytotoxic activity of heterocycle-substituted phthalimide derivatives. Chin Chem Lett. 2010;21:902–4.View ArticleGoogle Scholar
- Machado AL, Lima LM, Araújo-Jr JX, Fraga CAM, Koatzc VLG, Barreiroa EJ. Design, synthesis and antiinflammatory activity of novel phthalimide derivatives, structurally related to thalidomide. Bioorg Med Chem Lett. 2005;15:1169–72.PubMedView ArticleGoogle Scholar
- Malgorzata W, Katarzyna K. Synthesis and anticonvulsant evaluation of some N-substituted phthalimides. Acta Pol Pharm. 2009;3:249–57.Google Scholar
- Lee N-J, Jeong I-C, Cho M-Y, Jeon C-W, Yun B-C, Kim Y-O, et al. Synthesis and in vitro antitumor activity of phthalimide polymers containing podophyllotoxin. Eur Polym J. 2006;42:3352–9.View ArticleGoogle Scholar
- Lima LM, Brito FCF, Souza SD, Miranda ALP, Rodrigues CR, Fragaa CAM, et al. Novel phthalimide derivatives, designed as leukotriene D4 receptor antagonists. Bioorg Med Chem Lett. 2002;12:1533–5.PubMedView ArticleGoogle Scholar
- Santos JL, Yamasaki PR, Chin CM, Takashi CH, Pavan FR, Leite CQF. Synthesis and in vitro anti mycobacterium tuberculosis activity of a series of phthalimide derivatives. Bioorg Med Chem. 2009;17:3795–9.PubMedView ArticleGoogle Scholar
- Mohammadi-Farani A, Ahmadi A, Nadri H, Aliabadi A. Synthesis, docking and acetylcholinesterase inhibitory assessment of 2-(2-(4-Benzylpiperazin-1-yl)ethyl)isoindoline-1,3-dione with potential anti-alzheimer effects. Daru J Pharm Sci. 2013;21:47–55.View ArticleGoogle Scholar
- Foroumadi A, Mohammadi-Farani A, Garmsiri Mahvar M, Aliabadi A. Synthesis and evaluation of anti-acetylcholinesterase activity of 2-(2-(4-(2-Oxo-2-phenylethyl)piperazin-1-yl)ethyl)isoindoline-1,3-dione derivatives with potential anti-Alzheimer effects. Iran J Basic Med Sci. 2013;10(16):1049–54.Google Scholar
- Aliabadi A, Gholamine B, Karimi T. Synthesis and antiseizure evaluation of isoindoline-1,3-dione derivatives in mice. Med Chem Res. 2014;23:2736–43.View ArticleGoogle Scholar
- Aliabadi A, Foroumadi A, Safavi M, Kaboudian Ardestani S. Synthesis, molecular docking and cytotoxicity evaluation of 2-(4-substituted-benzyl)isoindoline-1,3-dione derivatives as anticancer agents. J Rep Pharm Sci. 2012;1:19–22.Google Scholar
- Ragavendran JV, Sriram D, Patel SK, Reddy IV, Bharathwajan N, Stables J. Design and synthesis of anticonvulsants from a combined phthalimide-GABA-anilide and hydrazone pharmacophore. Eur J Med Chem. 2007;42:146–51.PubMedView ArticleGoogle Scholar
- Mohammadi-Farani A, Foroumadi A, Rezvani Kashani M, Aliabadi A. N-Phenyl-2-p-tolylthiazole-4-carboxamide derivatives: Synthesis and cytotoxicity evaluation as anticancer agents. Iran J Basic Med Sci. 2014;17:502–8.PubMed CentralPubMedGoogle Scholar
- Aliabadi A, Eghbalian E, Kiani A. Synthesis and cytotoxicity evaluation of a series of 1,3,4-thiadiazole based compounds as anticancer agents. Iran J Basic Med Sci. 2013;11:1133–8.Google Scholar
- Aliabadi A, Hasanvand Z, Kiani A, Mirabdali SS. Synthesis and in vitro cytotoxicity assessment of N-(5-(Benzylthio)-1,3,4-thiadiazol-2-yl)-2-(4-(trifluoromethyl)phenyl)acetamide with potential anticancer activity. Iran J Pharm Res. 2013;4:687–93.Google Scholar
- Anthon GE, Barrett DM. Colorimetric method for the determination of lipoxygenase activity. J Agric Food Chem. 2001;49:32–7.PubMedView ArticleGoogle Scholar
- ArgusLab 4.0 Mark A. Thompson Planaria Software LLC, Seattle, WA http://www.arguslab.com.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.